Man Group’s Bicycle Therapeutics BCYC Stock Holding History

Man Group’s Portfolio BCYC Stock Details BCYC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-63,305	Closed	-$294K	–	2344
2026 Q1	$294K	Buy	63,305 +20,445	+48%	+$117K	﹤0.01%	2216
2025 Q4	$303K	Buy	42,860 +1,969	+5%	+$14.5K	﹤0.01%	2015
2025 Q3	$316K	Buy	40,891 +12,216	+43%	+$92.2K	﹤0.01%	1988
2025 Q2	$199K	Buy	+28,675	New	+$228K	﹤0.01%	2075
2024 Q1	–	Sell	-174,074	Closed	-$3.15M	–	2120
2023 Q4	$3.15M	Buy	+174,074	New	+$2.88M	0.01%	1133
2022 Q2	–	Hold	0	–	–	–	1791

Other funds holding BCYC

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

FIS

FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

LFCM

Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

GSK plc London $602M AUM

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Man Group's BCYC Position: Q2 2026 in Review

Man Group sold out of Bicycle Therapeutics (BCYC) in Q2 2026, closing a stake of 63,305 shares — an estimated $294K sold.

Man Group first reported a position in BCYC in Q4 2023 and held it in 5 quarters. The position peaked at $3.15M in Q4 2023. 104 funds tracked by Wall St. Rank hold BCYC as of Q2 2026.

Man Group reported no remaining Bicycle Therapeutics position as of Q2 2026 after selling out during the quarter.
Man Group sold 63,305 Bicycle Therapeutics shares in Q2 2026, an estimated $294K.
Man Group first reported a position in Bicycle Therapeutics in Q4 2023 and held it in 5 quarters.
Man Group's Bicycle Therapeutics position peaked at $3.15M in Q4 2023.
104 funds tracked by Wall St. Rank held Bicycle Therapeutics as of Q2 2026.

Based on Man Group's 13F filing for Q2 2026, filed 14 Aug 2026.